Alliancebernstein L.P. Arcus Biosciences, Inc. Transaction History
Alliancebernstein L.P.
- $290 Billion
- Q2 2025
A detailed history of Alliancebernstein L.P. transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 121,439 shares of RCUS stock, worth $2.47 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
121,439
Previous 113,260
7.22%
Holding current value
$2.47 Million
Previous $889,000
11.14%
% of portfolio
0.0%
Previous 0.0%
Shares
25 transactions
Others Institutions Holding RCUS
# of Institutions
210Shares Held
67MCall Options Held
3.18MPut Options Held
167K-
Black Rock Inc. New York, NY9.76MShares$199 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.56MShares$133 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct5.97MShares$121 Million0.11% of portfolio
-
Woodline Partners LP San Francisco, CA4MShares$81.4 Million0.19% of portfolio
-
Suvretta Capital Management, LLC New York, NY3.69MShares$75.1 Million1.03% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $1.47B
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...